联合抗过敏疗法加新鲜血浆治疗流行性出血热135例疗效观察

Study on Effect of Combined Antiallergic Therapy Plus Infusing Fresh Plasma for Patients with EHF in Middle-Late Stage

本文根据王文余等［１］研究ＩｇＥ及其介导的Ⅰ型变态反应参与流行性出血热（ＥＨＦ）早期发病过程，相继通过多项指标证明Ⅲ型变态反应参与了中晚期发病机制。由于ＥＨＦ病人血清中ＩｇＥ及ＩｇＧ水平不断升高，与相应抗原结合形成ＩｇＥ型和ＩｇＧ型等免疫复合物（ＩＣ），至中晚期达高峰，此时病人血清补体水平明显地下降，单核－巨噬细胞系统，红细胞系统清除免疫复合物功能低下，ＩＣ沉积于血管内膜及肾脏等组织，引起组织免疫损伤。依据这一理论，应用了联合抗过敏疗法加用新鲜血浆，治疗ＥＨＦ中晚期病人，获得显著疗效。

It has been sugessted that typeⅠand type Ⅲ allergy participated in onset of EHF in the early stage and middle-late stage respectively.Thus the treatment of combined antiallergy plus infusing fresh plasma was adopted for the patients in middle-late stage of EHF. The result showed that infusion of fresh plasma could augment the effectiveness of simple treatment of combined antiallergy.The curative rate was elevated to 98.9% in experiment group(90 cases),while that was 95.4% in control group(45 cases),The study concluded that the combined antiallergic therapy plus infusion of fresh plasma was effactive and that should be widely applied in treating patients in middle-late stage of EHF.